Preclinical studies explored VIP-R antagonists as cytostatic anti-cancer drugs16,61–63 but did not lead to clinical trials of VIP-R antagonists in humans, or to studies testing the potential of VIP-R antagonists to augment adaptive immunity. This evidence concerns the gene VIPR1 and cancer.